Successful percutaneous coronary intervention in a patient with severe haemophilia A using bivalirudin as the sole procedural anticoagulant
Author:
- 12 July 2005
- journal article
- case report
- Published by Wiley in Haemophilia
- Vol. 11 (4) , 415-417
Abstract
Summary. This article presents the case of a patient with severe haemophilia A who underwent successful multivessel percutaneous coronary intervention (PCI). Patients with haemophilia who are diagnosed with coronary artery disease (CAD) and require intervention present a challenge to doctors due to the high risks of bleeding. The patient was administered recombinant factor VIII pre‐ and post‐procedure. Anticoagulation during PCI was maintained with bivalirudin, a thrombin‐specific anticoagulant. There were no complications and the patient tolerated the procedure well. This case suggests that bivalirudin as the sole procedural anticoagulant can be safely used in patients with a very high risk of bleeding undergoing PCI.Keywords
This publication has 8 references indexed in Scilit:
- Haemophilias A and BThe Lancet, 2003
- Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade Compared With Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary InterventionJAMA, 2003
- Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty StudyAmerican Heart Journal, 2001
- Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and SafetyChest, 2001
- Acute left anterior descending artery occlusion in a hemophiliac A patient during recombinant factor VIII infusion: Treatment with coronary angioplastyCatheterization and Cardiovascular Interventions, 2000
- Do Hemophilia A and von Willebrand Disease Protect Against Carotid Atherosclerosis? A Comparative Study Between . Coagulopathics and Normal Subjects by Means of Carotid Echo-Color Doppler ScanClinical and Applied Thrombosis/Hemostasis, 1999
- Acute Myocardial Infarction Following Administration of Recombinant Activated Factor VII (Novo Seven) in a Patient with Haemophilia A and InhibitorThrombosis and Haemostasis, 1999
- Haemophilia protects against ischaemic heart disease: a study of risk factorsBritish Journal of Haematology, 1990